VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
Published on 08/07/2025 at 18:06 | prnewswire.co.uk
en | boerse | 67951363 |
